Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $570.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective raised by JPMorgan Chase & Co. from $560.00 to $570.00 in a report published on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the pharmaceutical company’s stock.

A number of other research analysts have also commented on VRTX. Stifel Nicolaus upped their price target on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a research note on Tuesday. Wells Fargo & Company increased their price target on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a report on Tuesday. Daiwa Securities Group raised their price objective on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. The Goldman Sachs Group raised their price objective on shares of Vertex Pharmaceuticals from $654.00 to $725.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Cantor Fitzgerald boosted their price objective on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an “overweight” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $596.44.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $542.50 on Tuesday. Vertex Pharmaceuticals has a one year low of $406.67 and a one year high of $568.67. The company has a market cap of $137.69 billion, a P/E ratio of 34.91, a P/E/G ratio of 2.84 and a beta of 0.28. The firm’s fifty day moving average price is $522.81 and its two-hundred day moving average price is $481.42. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 2.74.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the company earned $4.80 earnings per share. Equities analysts expect that Vertex Pharmaceuticals will post 16.50 earnings per share for the current year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Maryland State Retirement & Pension System raised its stake in Vertex Pharmaceuticals by 14.2% in the 3rd quarter. Maryland State Retirement & Pension System now owns 15,568 shares of the pharmaceutical company’s stock worth $8,139,000 after purchasing an additional 1,941 shares in the last quarter. Ritholtz Wealth Management boosted its holdings in Vertex Pharmaceuticals by 5.0% in the 3rd quarter. Ritholtz Wealth Management now owns 4,943 shares of the pharmaceutical company’s stock valued at $2,584,000 after purchasing an additional 234 shares during the period. UNIVEST FINANCIAL Corp boosted its holdings in Vertex Pharmaceuticals by 140.7% in the 3rd quarter. UNIVEST FINANCIAL Corp now owns 21,785 shares of the pharmaceutical company’s stock valued at $11,389,000 after purchasing an additional 12,736 shares during the period. Joel Isaacson & Co. LLC grew its position in shares of Vertex Pharmaceuticals by 6.8% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 614 shares of the pharmaceutical company’s stock worth $321,000 after purchasing an additional 39 shares in the last quarter. Finally, Jacobi Capital Management LLC grew its position in shares of Vertex Pharmaceuticals by 16.2% during the 3rd quarter. Jacobi Capital Management LLC now owns 1,318 shares of the pharmaceutical company’s stock worth $689,000 after purchasing an additional 184 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.